Malta - English - Medicines Authority

merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - clostridium botulinum, toxin type, a - powder for solution for injection - clostridium botulinum toxin type a 100 u - muscle relaxants

Malta - English - Medicines Authority

merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - clostridium botulinum, toxin type, a - powder for solution for injection - clostridium botulinum toxin type a 50 u - muscle relaxants

Malta - English - Medicines Authority

merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - clostridium botulinum, toxin type, a - powder for solution for injection - clostridium botulinum toxin type a 200 u - muscle relaxants

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sunward pharmaceutical sdn. bhd. - clostridium botulinum toxin type a -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - botulinim toxin type a, quantity: 100 u - injection, powder for - excipient ingredients: albumin; sodium chloride - botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following therapeutic indications: treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication. treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from a defined neurological illness (such as spinal cord injury or multiple sclerosis) and not controlled adequately by anticholinergic agents. prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). treatment of strabismus in children and adults.treatment of blepharospasm associated with dystonia, including benign blepharospasm and viith nerve disorders (specifically hemifacial spasm) in patients twelve years and older. treatment of cervical dystonia (spasmodic torticollis). treatment of focal spasticity of the upper and lower limb

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - botulinim toxin type a, quantity: 200 u - injection, powder for - excipient ingredients: albumin; sodium chloride - botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following therapeutic indications: treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication.,treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from a defined neurological illness (such as spinal cord injury or multiple sclerosis) and not controlled adequately by anticholinergic agents.,prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).,treatment of strabismus in children and adults.,treatment of blepharospasm associated with dystonia, including benign blepharospasm and viith nerve disorders (specifically hemifacial spasm) in patients twelve years and older.,treatment of cervical dystonia (spasmodic torticollis).,treatment of focal spasticity of the upper and lower lim

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - botulinim toxin type a, quantity: 50 u - injection, powder for - excipient ingredients: albumin; sodium chloride - botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following therapeutic indications: treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication. treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from a defined neurological illness (such as spinal cord injury or multiple sclerosis) and not controlled adequately by anticholinergic agents. prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). treatment of strabismus in children and adults.treatment of blepharospasm associated with dystonia, including benign blepharospasm and viith nerve disorders (specifically hemifacial spasm) in patients twelve years and older. treatment of cervical dystonia (spasmodic torticollis). treatment of focal spasticity of the upper and lower limbs, including dynamic equinus foot deformity, due to juvenile cerebral palsy in patients two years and older. treatment of severe primary hyperhidrosis of the axillae. treatment of focal spasticity in adults. treatment of spasmodic dysphonia. botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following cosmetic indications: temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow's feet and forehead lines) in adults.

United States - English - NLM (National Library of Medicine)

galderma laboratories, l.p. - botulinum toxin type a (unii: e211kpy694) (botulinum toxin type a - unii:e211kpy694) - botulinum toxin type a 300 u - dysport is indicated for the treatment of cervical dystonia in adults. dysport is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults less than 65 years of age. dysport is indicated for the treatment of spasticity in patients 2 years of age and older. dysport is contraindicated in patients with: - known hypersensitivity to any botulinum toxin products, cow's milk protein, or to any of the components in the formulation [see warnings and precautions (5.3)] .  this product may contain trace amounts of cow's milk protein [see description (11)] . - infection at the proposed injection site(s). risk summary there are no adequate and well-controlled clinical studies with dysport in pregnant women. dysport should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. dysport produced embryo-fetal toxicity in relation to maternal toxicity when given to pregn

United States - English - NLM (National Library of Medicine)

ipsen biopharmaceuticals, inc. - botulinum toxin type a (unii: e211kpy694) (botulinum toxin type a - unii:e211kpy694) - botulinum toxin type a 500 u - dysport is indicated for the treatment of cervical dystonia in adults. dysport is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults less than 65 years of age. dysport is indicated for the treatment of spasticity in patients 2 years of age and older. dysport is contraindicated in patients with: - known hypersensitivity to any botulinum toxin products, cow's milk protein, or to any of the components in the formulation [see warnings and precautions (5.3)]. this product may contain trace amounts of cow's milk protein [see description (11)] . - infection at the proposed injection site(s). risk summary there are no adequate and well-controlled clinical studies with dysport in pregnant women. dysport should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. dysport produced embryo-fetal toxicity in relation to maternal toxicity when given to pregnant rats and

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

allergan malaysia sdn bhd - clostridium botulinum toxin type a -